Production (Stage)
EyePoint Pharmaceuticals, Inc.
EYPT
$9.03
$0.171.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -86.00% | -84.86% | -3.42% | 18.06% | 22.97% |
| Total Depreciation and Amortization | 161.93% | 231.90% | 72.49% | -30.48% | -64.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.71% | 131.74% | -22.30% | -26.59% | -36.19% |
| Change in Net Operating Assets | -164.82% | -147.17% | -151.24% | -135.28% | 1,162.06% |
| Cash from Operations | -1,089.11% | -6,832.05% | -1,015.51% | -719.90% | 79.80% |
| Capital Expenditure | 25.26% | -16.34% | -42.89% | -76.38% | -68.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,798.69% | -128,256.55% | -307.66% | -310.24% | -114.10% |
| Cash from Investing | -1,274.69% | -6,517.04% | -322.20% | -322.39% | -120.48% |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | -100.00% |
| Total Debt Repaid | 99.60% | 99.77% | 99.87% | 100.00% | 17.91% |
| Issuance of Common Stock | -29.30% | -26.24% | 2,037.35% | 57,512.53% | 58,074.88% |
| Repurchase of Common Stock | 68.46% | -2,569.82% | -2,237.82% | -2,197.41% | -1,935.51% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 53.76% | 62.69% | 80.57% | 44.91% | -665.18% |
| Cash from Financing | -15.26% | -12.32% | 833.40% | 649.29% | 3,687.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -212.47% | -197.81% | -192.25% | -184.97% | 3,815.83% |